Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia

Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo Go, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Mariam S. Aziz, Nichola Cooper, Ivor S. Douglas, Sinisa Savic, Taryn Youngstein, Lorenzo Del Sorbo, Antonio Cubillo Gracian, David J. De La Zerda, Andrew Ustianowski, Min Bao, Sophie Dimonaco, Emily Graham, Balpreet Matharu, Helen Spotswood, Larry Tsai, Atul Malhotra
doi: https://doi.org/10.1101/2020.08.27.20183442
Ivan O. Rosas
1Baylor College of Medicine, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ivan.rosas@bcm.edu
Norbert Bräu
2James J. Peters Veterans Affairs Medical Center, Bronx, and Icahn School of Medicine at Mount Sinai, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Waters
3eStudy Site, Chula Vista, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronaldo Go
4Hacksensack University Medical Center, Hackensack, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley D. Hunter
5Intermountain Healthcare, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Bhagani
6Royal Free Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Skiest
7University of Massachusetts Medical School–Baystate, Springfield, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariam S. Aziz
8Rush University Medical Center, Chicago, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nichola Cooper
9Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivor S. Douglas
10Denver Health Medical Center, Denver, and University of Colorado, Anschutz School of Medicine, Aurora, CO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sinisa Savic
11Leeds Teaching Hospitals NHS Trust and National Institute for Health Research–Leeds Biomedical Research Centre, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taryn Youngstein
9Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Del Sorbo
12University Health Network, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Cubillo Gracian
13Hospital Universitario HM Sanchinarro, Centro Integral, Oncológico Clara Campal and Departamento de Ciencias Médicas Clínicas, Facultad de Medicina, Universidad CEU San Pablo, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. De La Zerda
14University of Miami Miller School of Medicine, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Ustianowski
15North Manchester General Hospital, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Bao
16Genentech, South San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Dimonaco
17Roche Products Ltd, Welwyn Garden City, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Graham
17Roche Products Ltd, Welwyn Garden City, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balpreet Matharu
17Roche Products Ltd, Welwyn Garden City, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Spotswood
17Roche Products Ltd, Welwyn Garden City, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry Tsai
16Genentech, South San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atul Malhotra
18University of California San Diego, La Jolla, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND COVID-19 is associated with immune dysregulation and hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody.

METHODS Patients hospitalized with severe COVID-19 pneumonia receiving standard care were randomized (2:1) to double-blinded intravenous tocilizumab 8 mg/kg or placebo. The primary outcome measure was clinical status on a 7-category ordinal scale at day 28 (1, discharged/ready for discharge; 7, death).

RESULTS Overall, 452 patients were randomized; the modified-intention-to-treat population included 294 tocilizumab-treated and 144 placebo-treated patients. Clinical status at day 28 was not statistically significantly improved for tocilizumab versus placebo (P=0.36). Median (95% CI) ordinal scale values at day 28: 1.0 (1.0 to 1.0) for tocilizumab and 2.0 (1.0 to 4.0) for placebo (odds ratio, 1.19 [0.81 to 1.76]). There was no difference in mortality at day 28 between tocilizumab (19.7%) and placebo (19.4%) (difference, 0.3% [95% CI, –7.6 to 8.2]; nominal P=0.94). Median time to hospital discharge was 8 days shorter with tocilizumab than placebo (20.0 and 28.0, respectively; nominal P=0.037; hazard ratio 1.35 [95% CI 1.02 to 1.79]). Median duration of ICU stay was 5.8 days shorter with tocilizumab than placebo (9.8 and 15.5, respectively; nominal P=0.045). In the safety population, serious adverse events occurred in 34.9% of 295 patients in the tocilizumab arm and 38.5% of 143 in the placebo arm.

CONCLUSIONS In this randomized placebo-controlled trial in hospitalized COVID-19 pneumonia patients, tocilizumab did not improve clinical status or mortality. Potential benefits in time to hospital discharge and duration of ICU stay are being investigated in ongoing clinical trials.

Trial registration ClinicalTrials.gov NCTG432G615

Competing Interest Statement

I.O.R. received a grant from Roche/Genentech during the conduct of the study; a grant and personal fees from Genentech outside the submitted work; and personal fees from Boehringer and Bristol-Myers Squibb outside the submitted work. N.B. institution received grant support from Roche/Genentech during the conduct of the study. M.W., M.S.A., N.C., I.S.D., S.S., T.Y., A.C.G., and D.J.D.L.Z. have nothing to disclose. R.G. has received consulting fees from F. Hoffmann-La Roche outside the submitted work. B.D.H. has received speaker bureau fees from Kite Pharmaceuticals outside the submitted work. S.B. has received personal fees from Gilead Sciences, Roche, and ViiV Healthcare outside the submitted work. D.S. institution received grant support from Roche/Genentech during the conduct of the study. L.D.S. received nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of the study. A.U. institution received grant support from Roche/Genentech during the conduct of the study, and he has received personal fees from Gilead Sciences outside the submitted work. M.B. and L.T. received a grant from Biomedical Advanced Research and Development Authority for the COVACTA study; are employees of Roche/Genentech; and have filed a patent for a method of treating pneumonia, including COVID-19 pneumonia, with an IL-6 antagonist. S.D. received a grant from Biomedical Advanced Research and Development Authority for the COVACTA study and is an employee and a shareholder of Roche Products Ltd. E.G. and B.M. are employees of Roche Products Ltd. H.S. is an employee and a shareholder of Roche Products Ltd. A.M. institution received grant support from Roche/Genentech during the conduct of the study; he has received funding from the National Institutes of Health outside the submitted work and medical education from Merck and Livanova outside the submitted work.

Clinical Trial

NCT04320615

Funding Statement

The study was funded by F. Hoffmann-La Roche Ltd and funded in part with federal funds received from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number HHSO100201800036C.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Informed consent was obtained for all enrolled patients. The study was conducted in accordance with the International Council for Harmonization E6 guideline for good clinical practice and the Declaration of Helsinki or local regulations, whichever afforded greater patient protection. The protocol was reviewed by institutional review boards or ethics committees.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)

https://www.clinicalstudydatarequest.com

https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 12, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo Go, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Mariam S. Aziz, Nichola Cooper, Ivor S. Douglas, Sinisa Savic, Taryn Youngstein, Lorenzo Del Sorbo, Antonio Cubillo Gracian, David J. De La Zerda, Andrew Ustianowski, Min Bao, Sophie Dimonaco, Emily Graham, Balpreet Matharu, Helen Spotswood, Larry Tsai, Atul Malhotra
medRxiv 2020.08.27.20183442; doi: https://doi.org/10.1101/2020.08.27.20183442
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo Go, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Mariam S. Aziz, Nichola Cooper, Ivor S. Douglas, Sinisa Savic, Taryn Youngstein, Lorenzo Del Sorbo, Antonio Cubillo Gracian, David J. De La Zerda, Andrew Ustianowski, Min Bao, Sophie Dimonaco, Emily Graham, Balpreet Matharu, Helen Spotswood, Larry Tsai, Atul Malhotra
medRxiv 2020.08.27.20183442; doi: https://doi.org/10.1101/2020.08.27.20183442

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (501)
  • Anesthesia (110)
  • Cardiovascular Medicine (1233)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (529)
  • Epidemiology (10012)
  • Forensic Medicine (5)
  • Gastroenterology (498)
  • Genetic and Genomic Medicine (2448)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1636)
  • Health Policy (751)
  • Health Systems and Quality Improvement (635)
  • Hematology (248)
  • HIV/AIDS (532)
  • Infectious Diseases (except HIV/AIDS) (11860)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2277)
  • Nursing (139)
  • Nutrition (350)
  • Obstetrics and Gynecology (452)
  • Occupational and Environmental Health (534)
  • Oncology (1245)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (155)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4828)
  • Radiology and Imaging (834)
  • Rehabilitation Medicine and Physical Therapy (490)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (226)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)